compared to its average ratio and a 36-month beta value of 1.66.
The public float for BLCM is 8.50M, and currently, short sellers hold a 1.05% ratio of that float. The average trading volume of BLCM on March 16, 2023 was 54.31K shares.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
BLCM) stock’s latest price update
Bellicum Pharmaceuticals Inc. (NASDAQ: BLCM)’s stock price has decreased by -50.14 compared to its previous closing price of 0.86. However, the company has experienced a -54.77% decline in its stock price over the last five trading sessions.
BLCM’s Market Performance
Bellicum Pharmaceuticals Inc. (BLCM) has seen a -54.77% fall in stock performance for the week, with a -65.14% decline in the past month and a -55.83% plunge in the past quarter. The volatility ratio for the week is 15.56%, and the volatility levels for the past 30 days are at 13.18% for BLCM. The simple moving average for the last 20 days is -55.71% for BLCM stock, with a simple moving average of -62.06% for the last 200 days.
Analysts’ Opinion of BLCM
Many brokerage firms have already submitted their reports for BLCM stocks, with Wells Fargo repeating the rating for BLCM by listing it as a “Equal Weight.” The predicted price for BLCM in the upcoming period, according to Wells Fargo is $4.50 based on the research report published on October 30th of the previous year 2020.
BLCM Trading at -60.12% from the 50-Day Moving Average
After a stumble in the market that brought BLCM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -80.51% of loss for the given period.
Volatility was left at 13.18%, however, over the last 30 days, the volatility rate increased by 15.56%, as shares sank -63.97% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -40.44% lower at present.
During the last 5 trading sessions, BLCM fell by -54.77%, which changed the moving average for the period of 200-days by -68.24% in comparison to the 20-day moving average, which settled at $0.9301. In addition, Bellicum Pharmaceuticals Inc. saw -40.44% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for BLCM
Current profitability levels for the company are sitting at:
- -393.35 for the present operating margin
- +97.77 for the gross margin
The net margin for Bellicum Pharmaceuticals Inc. stands at -156.53. Equity return is now at value -102.60, with -40.50 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 7.32.
Conclusion
To put it simply, Bellicum Pharmaceuticals Inc. (BLCM) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
